Abstract:Accumulation of extracellular matrix (ECM) proteins in glomerulus is one of early features of diabetic nephropathy. Glomerular mesangial cell (MC) is the major source of ECM. Inhibitor of Myogenic Family isoform a (I‐mfa) is a cytosolic protein interacting with components of Wnt/β‐catenin pathway and of store‐operated Ca 2+ signaling pathway, both of which are involved in the development of diabetic nephropathy. The present study was carried out to determine if I‐mfa in MCs contributed to renal injury in diabetic mice. Twelve male mice were randomly divided into 4 groups (3 mice each group): non‐diabetes, diabetes, diabetes treated with scramble siRNA, and diabetes treated with siRNA against I‐mfa. Diabetes was generated by multiple low‐dose streptozotocin (STZ, 50 mg/kg) injections (intraperitoneal, once one day for 5 days) at an age of 6 weeks. Mice in group of non diabetes were injected with 10 mM citrate buffer (vehicle). Diabetes was indicated by a fasting blood glucose level of > 300 mg/dl. Scramble or I‐mfa siRNA treatment started 24 weeks after STZ injection and the treatment lasted 2 weeks. All siRNAs (10 mg/kg body weight) were delivered by our recently established‐targeted nanoparticle/siRNA delivery system which is glomerular mesangial cell specific. We found that STZ treatment significantly increased blood glucose level after 4 weeks of injection and reduced body weight 26 weeks after treatment. I‐mfa siRNA treatment did not improve hyperglycemia, but lessened renal hypertrophy in STZ mice. Furthermore, diabetic mice showed significantly greater 24 hour urine output and this diabetic uresis was compromised by I‐mfa siRNA treatment. Although knocking down I‐mfa did not mitigate albuminuria, it lowered the level of blood urea nitrogen in diabetic mice. Consistent with the functional data, histological examination showed improved mesangial expansion and glomerular fibrosis in I‐mfa siRNA‐treated STZ mice. Immunohistochemical examination showed a significant reduction of protein abundance of glomerular fibronectin and collagen IV in the siRNA‐treated diabetic mice. Taken together, our data indicate that I‐mfa in MCs is involved in the development of diabetic kidney disease and thus, could be a potential therapeutic target for diabetic nephropathy. Support or Funding Information AHA Southwestern Affiliate; Harry S. Moss Heart Trust; University Outstanding Talent Cultivated Projects of Anhui Province, China (gxfxZD2016118 and gxfxZD2016162)

Malignant fibrous histiocytoma amplified sequence 1 (MFHAS1) alleviates inflammation and renal fibrosis in diabetic nephropathy by inhibiting TLR4.

Malignant fibrous histiocytoma amplified sequence 1 alleviates inflammation and renal fibrosis in diabetic nephropathy by inhibiting TLR4

Bone Marrow Mesenchymal Stem Cells Ameliorated Kidney Fibrosis by Attenuating TLR4/NF-κB in Diabetic Rats.

Magnoflorine Ameliorates Inflammation and Fibrosis in Rats With Diabetic Nephropathy by Mediating the Stability of Lysine-Specific Demethylase 3A

IGF-1R Inhibitor Ameliorates Diabetic Nephropathy with Suppressed HMGN1/TLR4 Pathway

High-Mobility Group Nucleosome-Binding Protein 1 Mediates Renal Fibrosis Correlating with Macrophages Accumulation and Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy Mice Model.

Targeting mammalian serine/threonine-protein kinase 4 through Yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchestrated renal fibrosis

High Glucose Stimulates Expression of MFHAS1 to Mitigate Inflammation Via Akt/HO-1 Pathway in Human Umbilical Vein Endothelial Cells

In Vivo Knockdown of I‐mfa Using The Targeted Nanoparticle Delivery System Ameliorated Renal Injury in Diabetic Mice

Dihydromyricetin ameliorates diabetic renal fibrosis via regulating SphK1 to suppress the activation of NF-κB pathway

LINC01232 targeting miR-1250-3p/MSH2 axis attenuates mesangial cell proliferation and fibrosis in diabetic nephropathy

BML-111 Attenuates High Glucose-Induced Inflammation, Oxidative Stress and Reduces Extracellular Matrix Accumulation Via Targeting Nrf2 in Rat Glomerular Mesangial Cells

Mangiferin Alleviates Renal Interstitial Fibrosis in Streptozotocin-Induced Diabetic Mice through Regulating the PTEN/PI3K/Akt Signaling Pathway

Knockdown of transient receptor potential melastatin 2 reduces renal fibrosis and inflammation by blocking transforming growth factor-β1-activated JNK1 activation in diabetic mice

HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4

DsbA-L alleviates tubular injury in diabetic nephropathy by activating mitophagy through maintenance of MAM integrity

MiR‐874 Alleviates Renal Injury and Inflammatory Response in Diabetic Nephropathy Through Targeting Toll‐like Receptor‐4

Overexpression of Mm9_circ_013935 Alleviates Renal Inflammation and Fibrosis in Diabetic Nephropathy Via the Mir-153-3p/nfic Axis

LncTUG1 ameliorates renal tubular fibrosis in experimental diabetic nephropathy through the miR-145-5p/dual-specificity phosphatase 6 axis

Hydroxysafflor yellow A improves diabetes-induced renal fibrosis

Inhibition of STIM1 alleviates high glucose-induced proliferation and fibrosis by inducing autophagy in mesangial cells